ARVN
ARVINAS, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.42
+4.65%Year over year
Reported trailing growth
- Revenue
- -11.8%
- EBITDA
- +67.0%
- EBIT
- +71.2%
- EPS
- +81.5%
- Free cash flow
- +51.5%
- Operating cash flow
- +51.7%
Forward estimates
Based on analyst estimates
- Revenue
- -74.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +26.0%
- EBITDA
- +60.7%
- EBIT
- +54.1%
- Net income
- +59.4%
- EPS
- +53.8%
- Free cash flow
- -5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026